}v\QX/ /! c +hjWfhX c~HU4@Hf@UW S*-V2 P 92RL) j}TF{Sqq2 ^xQP-uPDiQi- ,5!Y fo}ytfPfo {B Fu4k024o tus@ 4=f)8P=|@4=/4)AHM4X HjsjU W)`rv$W ]5c}N/j5-9j a_4O_/YRZC/Raa %bO5VE7b^u7 *jx\jSrt O9//*0//M. FJ, #B\nA5\ H] n)= x(v %%0Z~ 1R16uq`q /8 XH1J L8l}A Lae |=`S`D1`H L8 M8Ai ~,X;f ^/s.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/-ru7mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.